Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DVS-233 · 11 trials · 7 indications
| Name | Type | Description |
|---|---|---|
| DVS-233 | DRUG | - |
| DVS-233 SR | DRUG | - |
| DVS-233 SR (desvenlafaxine sustained release ) | DRUG | - |
| Venlafaxine ER | DRUG | - |
Inclusion Criteria: * Postmenopausal women of age 40 to 65 seeking treatment for hot flashes with last natural menstrual period (LNMP) completed at least 12 months prior to screening. * Minimum of 7 moderate to severe hot flashes per day or 50 per week recorded for 7 consecutive days * Body Mass In...
DVS-233 is an investigational small molecule being studied for the treatment of vasomotor symptoms associated with menopause, as well as for major depressive disorder. It is being developed by Pfizer, Inc. (NYSE: PFE) and has completed Phase 3 clinical trials in these indications.
DVS-233 is a small molecule being developed for psychiatric and menopausal conditions. Its specific molecular target has not been disclosed in the available clinical trial information. The drug is being studied for its effects on vasomotor symptoms and major depressive disorder.
DVS-233 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. Pfizer has conducted multiple Phase 3 clinical trials of DVS-233 for menopause-related vasomotor symptoms and major depressive disorder.
DVS-233 has completed Phase 3 clinical trials. All seven recorded trials for DVS-233 are completed, with no active trials currently ongoing. The drug remains investigational and has not been reported as approved by regulatory authorities.
DVS-233 has been studied in seven completed clinical trials, including NCT00092911 in major depressive disorder, NCT00195546 and NCT00256685 in vasomotor symptoms associated with menopause, and NCT00421031 for relief of vasomotor symptoms. These trials enrolled a total of 2,443 participants.
DVS-233 is an investigational compound being developed by Pfizer. The clinical trial records for DVS-233 do not list alternative names, so it is not identified as desvenlafaxine in the available data. The drug is being studied for vasomotor symptoms and major depressive disorder.